Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type Journal Article
PMID (25093639)
Authors Dong W, van Ginkel JW, Au KY, Alemany R, Meulenberg JJ, van Beusechem VW
Title ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.
Journal Human gene therapy
Vol 25
Issue 10
Date 2014 Oct
URL
Abstract Text Improving the antitumor potency of current oncolytic adenoviruses represents one of the major challenges in development of these viruses for clinical use. We have generated an oncolytic adenovirus carrying the safety-enhancing E1AΔ24 deletion, the potency-enhancing T1 mutation, and the infectivity-enhancing fiber RGD modification. The results of in vitro cytotoxicity assays on 15 human cancer cell lines derived from different tumor types demonstrated that ORCA-010 is more potent than Ad5-Δ24RGD or ONYX-015. As ORCA-010 will initially be developed for the treatment of prostate cancer, selectivity experiments were performed using primary human prostate cells. ORCA-010 killed cancer cells more effectively than these primary human cells. In both primary prostate fibroblasts and epithelial cells, ORCA-010 was as safe as Ad5-Δ24RGD. Evaluation of ORCA-010 in in vivo xenograft tumor models in nude mice showed that ORCA-010 significantly inhibited growth of prostate, lung, and ovarian tumors and conferred prolonged survival of tumor-bearing animals. Furthermore, we observed a substantial increase in infectious viral particles in tumors injected with ORCA-010. The number of infectious viral particles increased after treatment and infectious particles remained present up to at least 4 weeks posttreatment. Intratumoral virus replication was associated with substantial necrosis and fibrosis. In conclusion, ORCA-010 is more potent than earlier generation oncolytic adenoviruses, without demonstrating increased toxicity. ORCA-010 exerted strong in vivo antitumor activity and is therefore a suitable candidate for clinical evaluation.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
ORCA-010 ORCA 010|ORCA010 ORCA-010 is an engineered oncolytic serotype 5 adenovirus (Ad5), which potentially induces enhanced cytotoxicity against tumor cells and inhibits tumor growth (PMID: 25093639).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lung adenocarcinoma not applicable ORCA-010 Preclinical - Cell line xenograft Actionable In a preclinical study, ORCA-010 treatment induced cytotoxicity in a lung adenocarcinoma cell line in culture, and inhibited tumor growth and increased survival in a cell line xenograft model (PMID: 25093639). 25093639
Unknown unknown ovarian cancer not applicable ORCA-010 Preclinical - Cell line xenograft Actionable In a preclinical study, ORCA-010 treatment inhibited tumor growth and increased survival in a cell line xenograft model of ovarian cancer (PMID: 25093639). 25093639
Unknown unknown prostate cancer not applicable ORCA-010 Preclinical - Cell line xenograft Actionable In a preclinical study, ORCA-010 treatment induced cytotoxicity in a prostate cancer cell line in culture, and inhibited tumor growth and increased survival in a cell line xenograft model (PMID: 25093639). 25093639